Long‐term Safety of Pioglitazone versus Glyburide in Patients with Recently Diagnosed Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Study Objective. To evaluate the long‐term safety and efficacy of glyburide versus pioglitazone in patients with a recent diagnosis of type 2 diabetes mellitus. Design. Prospective, randomized, multicenter, double‐blind trial with a 16‐week titration period and a 40‐week maintenance period. Setting. Sixty‐five investigative sites in the United States and Puerto Rico. Patients. Five hundred two subjects with a recent diagnosis of type 2 diabetes that was unsuccessfully treated with diet and exercise were randomly assigned to study treatment. Of the 251 patients in each treatment group, 128 (51.0%) glyburide‐treated patients and 134 (53.4%) pioglitazone‐treated patients completed the study. Interventions. Dosages of randomly assigned glyburide and pioglitazone were titrated every 4 weeks for 16 weeks in 5‐mg/day and 15‐mg/day increments, respectively, until a fasting plasma glucose level between 69 and 141 mg/dl was achieved. The optimized regimen was maintained during the subsequent 40‐week double‐blind phase. Measurements and Main Results. At week 56, glyburide and pioglitazone improved glucose control comparably (change in hemoglobin A 1c −2.02% and −2.07%, respectively, p=0.669). Withdrawal due to lack of efficacy or adverse events occurred more frequently with glyburide (20.8%) than pioglitazone (12.8%, p<0.032). Significantly higher percentages of glyburide‐ than pioglitazone‐treated patients had a hypoglycemic (24.3% vs 4.4%, p=0.0001) or cardiac (8.8% vs 4.4%, p=0.0478) event. Edema (4.8% vs 7.9%, p=0.1443) and weight gain (4.4% vs 4.0%, p=0.8238) did not differ significantly between the glyburide and pioglitazone groups. Only a few patients discontinued study drug because of weight gain (one glyburide, one pioglitazone), edema (one pioglitazone), or a cardiac event (two glyburide). Conclusion. With long‐term treatment, both glyburide and pioglitazone resulted in comparable glycemic control; however, pioglitazone was associated with less hypoglycemia and fewer withdrawals due to lack of efficacy or adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201
Cited by
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 551
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 400
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253
“3 Rosiglitazone vs metformin/glyburide 8 mg/d 48 92 W:60 M:32 1456 W:645 M:811 108 W:51 M:57 2895 W:1195 M:1700 Nissen SE [26] 2008 Patients with coronary disease and type 2 diabetes 60 Pioglitazone vs glimepiride 30–45 mg/d 18 8 W:6 M:2 270 W:84 M:186 0 W:0 M:0 273 W:93 M:180 Seufert J(a) [27] 2008 Patients with type…”
Iglay, K., Cartier, S. E., Rosen, V. M., Zarotsky, V., Rajpathak, S. N., Radican, L., & Tunceli, K. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1053048 · Cited by 157
Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001992 · Cited by 143
Kemp, D. E., Ismail-Beigi, F., Ganocy, S. J., Conroy, C., Gao, K., Obral, S., Fein, E., Findling, R. L., & Calabrese, J. R. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.033 · Cited by 109
“Pioglitazone effectively lowers fasting blood glucose levels and also reduces glycosylated hemoglobin, but is associated with a low likelihood of hypoglycemia (Jain et al., 2006).”
BackgroundZhou, Y., Huang, Y., Ji, X., Wang, X., Shen, L., & Wang, Y. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz252 · Cited by 81
Metadata
- Authors
- Jain, R., Osei, K., Kupfer, S., Perez, A. T., Zhang, J., & Lannon, M.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2006-10
- Volume
- 26
- Issue
- 10
- Pages
- 1388-1395
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2002959668
- Cited by
- 47
- References
- 1
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.